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ties encountered and offer recommendations for using
such databases to examine provider prescribing prac-
tices, patient compliance, and outcomes of ADHD-related
care. The following methodological issues will be dis-
cussed: 1) determining the presence of specific psychiatric
disorders and their comorbidities from pharmacy benefits
databases; 2) using pharmacy benefits databases and pa-
tient telephone and mail surveys to distinguish discontin-
ued psychotropic treatment from patient noncompliance
and medication switching; 3) applying health services uti-
lization and pharmacy databases to determine small area
variation in ADHD care; 4) examining the impact of be-
havioral health care carve-outs on analyses of patient
outcomes; 5) employing findings to benchmark existing
quality of care, calculate rates of provider adherence to
guidelines, identify best practices, and evaluate impact of
interventions on outcomes of patients with ADHD.
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OBJECTIVES: The objectives of this workshop are to de-
scribe various types of linkable clinical and administra-
tive claims data, review selected case studies, and high-
light the strengths and limitations of these databases.
PARTICIPANTS WHO WOULD BENEFIT: Those in-
volved in planning, designing, implementing, and using
data from retrospective database studies would benefit
from this workshop.
Administrative claims are increasingly used for outcomes
research studies, despite known limitations associated
with data reliability and validity, and a lack of clinical
content. In recent years, efforts have been made to link
claims to other sources, such as disease registries and
clinical laboratory files, to create richer databases for re-
search purposes. These linked data sources offer the po-
tential for improved accuracy in case identification and
outcomes ascertainment. For example, study patients can
be selected based on their presence in a disease registry
instead of relying on diagnoses reported on medical claim
forms, and clinical laboratory files can be used to evalu-
ate the success or failure of therapy. In this workshop, we
will review, via case studies from oncology and diabetes,
the content of linkable clinical and claims databases, the
specific ways in which such data have been used in pub-
lished outcomes studies, and the remaining limitations of
this record linkage approach. Participants will learn how
clinical data can be applied to strengthen studies of treat-
ment costs and the burden of illness, and they will gain
an appreciation of the improvements that linked data
sources can make to the pharmacoeconomics and out-
comes research fields. One case study will review applica-
tions of the SEER-Medicare database, which includes a
linkage between cancer registry data and Medicare ad-
ministrative claims for approximately 14% of U.S. cancer
cases across 17 diverse regions. The other illustration will
describe published studies of the economic benefits of im-
proving glycemic control among diabetes patients, in
which claims data from several managed-care organiza-
tions were linked to glycosylated hemoglobin test results.
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OBJECTIVES: The purposes of the workshop are to
demonstrate a systematic method to compare published
models developed for a same disease and to point out the
importance of validation of model structure, data input
and outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Pharmaco-
economic and outcomes researchers involved in modeling
and/or in the area of DVT.
In the clinical and health economic literature, 11 different
models from different researchers are published in the
area of DVT prevention with heparins. These models
generally compare standard heparin with one of the low
molecular weight heparins in order to assess the health
economic consequences of better prevention at a higher
price. All models differ in many aspects of study design
and methodology: perspective, target audience, patient
population, patient subpopulations, choice of compara-
tor(s) and justification of this choice, medical manage-
ment patterns and corresponding decision trees, clinical
data input and reporting, economic data input and re-
porting, dealing with uncertainties, validation, conclu-
sions and extrapolations. This lack of uniformity in de-
sign and methods within a same research topic leads to
incomparable outcomes and conclusions. The workshop
is designed to discuss with the audience the strengths and
weaknesses of all models, and to have the audience sug-
gest solutions for better design, reporting and communi-
cations of results in this area and for decision models in
general. A novel consensus method, leading to a new
model, attempting to bring together the best elements of ex-
isting models, is proposed for discussion with the audience.
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